| Bioactivity | HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR triple mutations and has anti-tumor activity[1]. |
| Name | HJM-561 |
| CAS | 2570251-68-0 |
| Formula | C45H51ClN9O5P |
| Molar Mass | 864.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Du Y, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066. |
HJM-561
CAS: 2570251-68-0 F: C45H51ClN9O5P W: 864.37
HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.